News & Blogs

TailorMed Expands Partnership with KabaFusion to Increase Patient Access to Financial Assistance

Long-term Engagement will Result in Lower Out-of-Pocket Expenses for Home Infusion Treatments

June 3, 2025
TailorMed and KabaFusion Expand Partnership to Improve Patient Affordability
Share

New York, June 3, 2025TailorMed, a leading healthcare technology innovator, announced it has signed a renewal agreement with home infusion company KabaFusion to help patients afford critical treatments. KabaFusion will continue to leverage TailorMed’s comprehensive platform and robust affordability network to identify relevant financial resources and expedite patient enrollment in appropriate programs. The agreement extends the partnership between TailorMed and KabaFusion, which began in 2023.

TailorMed’s network includes premier infusion companies, pharmacies, providers, life science companies, and other stakeholders dedicated to transforming medication affordability and access. Its solutions enable healthcare organizations and patients to find cost-saving resources and streamline enrollment processes. Since its inception, TailorMed has secured over $5 billion in financial assistance for patients.

“Since its founding in 2010, KabaFusion has set the standard for providing exceptional home infusion services, and is committed to helping its patients access these treatments without incurring the financial hardships that are too often associated with specialty care,” explained Bryan Bloom, TailorMed’s national director of sales. “We are proud that KabaFusion has elected to expand our partnership and increase access to vital assistance programs. It demonstrates the importance the company places on addressing affordability and delivering positive, outcomes-oriented patient experiences.”

KabaFusion is a pharmacist-owned home infusion company that specializes in IVIG, SCIG, and acute home-infusion therapies. The company is one of the nation’s fastest-growing home infusion providers, maintaining state-of-the-art compounding pharmacies around the country and serving patients in over 46 states.

“Our overarching goal is always to provide the highest quality home infusion care to our patients—regardless of their health, personal, or economic situations,” said Fawad Piracha, chief clinical officer of KabaFusion.

To learn more about TailorMed, please visit https://tailormed.co/.

{{boilerplate}}

About KabaFusion

Headquartered in Cerritos, CA and Lexington, MA, KabaFusion is a national provider of essential chronic and acute infusion therapies. The company serves patients in 46 states through its nationwide network of home infusion pharmacies, alternative infusion sites, and home health agencies. KabaFusion was founded in 2010 by Chief Executive Officer Dr. Sohail Masood, a pioneer in patient focused infusion therapies with more than 30 years of clinical experience. The Company is dedicated to working proactively with patients, healthcare practitioners, and payors to provide comprehensive support before, during, and after treatment. For more information, visit www.KabaFusion.com.

{{tailormed-contact}}

{{pr-contact}}

No items found.

About TailorMed

TailorMed is the medication success platform removing every barrier across the patient medication journey, from access and affordability through adherence and ongoing care. Through a connected network spanning 945+ hospitals, 4,700+ clinics, 3,100+ pharmacies, 100+ life sciences programs, and 6,000+ support programs, TailorMed has supported over 75 million patients and secured more than $7.4 billion in financial assistance since 2020. TailorMed's platform, including TailorMed Core, TailorMed Connect, TailorMed Complete, TailorMed Amplify, and TailorMed Alliance, connects patients, providers, pharmacies, and life sciences companies through one coordinated network designed to reach every patient at every step of their medication journey. Learn more at tailormed.com.

Media Contacts:

Jennifer Martin, VP, Marketing
jenm@tailormed.co

PR Contacts:

Glenn Goldberg
Parallel Communications Group
+1 516 776-3282
𝕏: @Parallel_PR
LinkedIn
ggoldberg@parallelpr.com